Template:COVID-19 vaccine effectiveness

Add links
Source: Wikipedia, the free encyclopedia.

Edit with VisualEditor

Main article: COVID-19 vaccine clinical research
(
)
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs
Asymptomatic Symptomatic Hospitalization Death
Oxford–AstraZeneca 70% (69–71%) Not reported 87% (85–88%) 90% (88–92%) Brazil [1]
Not reported 89% (78–94%)[i] Not reported Not reported England [3]
Not reported Not reported Not reported 89%[ii] Argentina [4]
72% (69–74%) Not reported Not reported 88% (79–94%) Hungary [5]
Pfizer–BioNTech 92% (91–92%) 97% (97–97%) 98% (97–98%) 97% (96–97%) Israel [6]
92% (88–95%) 94% (87–98%) 87% (55–100%) 97%[ii] Israel [7][8]
83% (83–84%) Not reported Not reported 91% (89–92%) Hungary [5]
Not reported 78% (77–79%) 98% (96–99%) 96% (95–97%) Uruguay [9]
85% (74–96%) Not reported Not reported England [10]
90% (68–97%) Not reported 100%[ii][iii] United States [11]
Moderna 89% (87–90%) Not reported Not reported 94% (91–96%) Hungary [5]
90% (68–97%) Not reported 100%[ii][iii] United States [11]
Sinopharm BIBP Not reported Not reported Not reported 84%[ii] Argentina [4]
69% (67–70%) Not reported Not reported 88% (86–89%) Hungary [5]
50% (49–52%) Not reported Not reported 94% (91–96%) Peru [12]
Sputnik V Not reported 98%[ii] Not reported Not reported Russia [13][14]
Not reported 98%[ii] 100%[ii][iii] 100%[ii][iii] United Arab Emirates [15]
Not reported Not reported Not reported 93%[ii] Argentina [4]
86% (84–87%) Not reported Not reported 98% (96–99%) Hungary [5]
CoronaVac 54% (53–55%) Not reported 73% (72–74%) 74% (73–75%) Brazil [1]
Not reported 66% (65–67%) 88% (87–88%) 86% (85–88%) Chile [16][17]
Not reported 60% (59–61%) 91% (89–93%) 95% (93–96%) Uruguay [9]
Not reported 94%[ii] 96%[ii] 98%[ii] Indonesia [18][19]
Not reported 80%[ii] 86%[ii] 95%[ii] Brazil [20][21]
Sputnik Light 79% (75–82%)[ii][iv] Not reported 88% (80–92%)[ii][iv] 85% (75–91%)[ii][iv] Argentina [22]
  1. ^ Data collected while the Alpha variant was already dominant.[2]
  2. ^ a b c d e f g h i j k l m n o p q r s A confidence interval was not provided, so it is not possible to know the accuracy of this measurement.
  3. ^ a b c d No cases detected in study.
  4. ^ a b c Participants aged 60 to 79.
(
)
Initial course Booster dose Initial effectiveness by severity of COVID-19 Study location Refs
Asymptomatic Symptomatic Hospitalization Death
CoronaVac CoronaVac Not reported 80%[I] 88%[I] Not reported Chile [23]
Pfizer–BioNTech Not reported 90%[I] 87%[I] Not reported Chile [23]
Oxford–AstraZeneca Not reported 93%[I] 96%[I] Not reported Chile [23]
  1. ^ a b c d e f A confidence interval was not provided, so it is not possible to know the accuracy of this measurement.

References

These references will appear in the article, but this list appears only on this page.
  1. ^ a b Cerqueira-Silva T, Oliveira VA, Boaventura VS, Pescarini JM, Júnior JB, Machado TM, Flores-Ortiz R, Penna GO, Ichihara MY, de Barros JV, Barreto ML, Werneck GL, Barral-Netto M (February 2022). "Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study". Lancet Regional Health. Americas. 6: 100154. doi:10.1016/j.lana.2021.100154. PMC 8692070. PMID 34957437. S2CID 237292831.
  2. ^ COVID-19 vaccine surveillance report (week 21) (PDF) (Technical report). Public Health England. 27 May 2021. GOV-8481.
  3. ^ COVID-19 vaccine surveillance report (week 20) (PDF) (Technical report). Public Health England. 20 May 2021. GOV-8401.
  4. ^ a b c "Ministros de Salud de todo el país consensuaron redoblar esfuerzos para completar los esquemas de vacunación en mayores de 40 años" [Health ministers from all over the country agreed to redouble their efforts to complete vaccination schedules in people over 40 years of age] (in Spanish). Government of Argentina. Ministry of Health (Argentina). 1 July 2021. Retrieved 12 July 2021.
  5. ^ a b c d e Vokó Z, Kiss Z, Surján G, Surján O, Barcza Z, Pályi B, Formanek-Balku E, Molnár GA, Herczeg R, Gyenesei A, Miseta A (2021-11-25). "Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary - The HUN-VE study". Clinical Microbiology and Infection. Table 2. doi:10.1016/j.cmi.2021.11.011. ISSN 1198-743X.
  6. ^ Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S (May 2021). "Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data". Lancet. 397 (10287): 1819–1829. doi:10.1016/S0140-6736(21)00947-8. PMC 8099315. PMID 33964222.
  7. ^ Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD (April 2021). "BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting". New England Journal of Medicine. 384 (15): 1412–23. doi:10.1056/NEJMoa2101765. PMC 7944975. PMID 33626250.
  8. ^ "Real-World Evidence Confirms High Effectiveness of Pfizer–BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared". Pfizer. 11 March 2021. Retrieved 1 April 2021.
  9. ^ a b "Tercer estudio de efectividad de vacunación anti SARS-CoV-2 en Uruguay al 30 de junio de 2021" [Third study of effectiveness of vaccination against SARS-CoV-2 in Uruguay as of June 30, 2021]. Ministerio de Salud Pública (in Spanish). 3 July 2021. Retrieved 7 July 2021.
  10. ^ Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, Islam J, Karagiannis I, Munro K, Khawam J, Chand MA, Brown CS, Ramsay M, Lopez-Bernal J, Hopkins S (May 2021). "COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study". The Lancet. 397 (10286): 1725–35. doi:10.1016/S0140-6736(21)00790-X. ISSN 0140-6736. PMC 8064668. PMID 33901423.
  11. ^ a b Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LE, Caban-Martinez AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann KT, Stefanski E, Edwards LJ, Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic L, Wesley MG, Lamberte JM, Sun X, Smith ME, Phillips AL, Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK, Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM, Hunt DR, Arvay ML, Kutty P, Fry AM, Gaglani M (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers – Eight U.S. Locations, December 2020 – March 2021" (PDF). MMWR Morb Mortal Wkly Rep. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460.
  12. ^ Silvia-Valencia J, Soto-Becerra P, Escobar-Agreda S, Fernández-Navarro M, Moscoso-Porras M, Solari L, Mayta-Tristan P (22 July 2021). Efectividad de la vacuna BBIBP-CorV para prevenir infección y muerte en personal de salud [Effectiveness of the BBIBP-CorV vaccine to prevent infection and death in health personnel] (Technical report) (in Spanish). Ministry of Health of Peru. Tabla 4, figura 2.
  13. ^ "Russia's Sputnik V vaccine 97.6% effective in real-world study". Reuters. Moscow. 19 April 2021. Retrieved 21 April 2021.
  14. ^ "Sputnik V demonstrates 97.6% efficacy according to analysis of data from 3.8 million vaccinated persons in Russia making it the most efficient COVID-19 vaccine in the world" (Press release). Moscow: Russian Direct Investment Fund. 19 April 2021. Retrieved 21 April 2021.
  15. ^ "Sputnik V has demonstrated 97.8% efficacy against COVID cases and 100% efficacy against severe cases of COVID in UAE" (Press release). Moscow: Russian Direct Investment Fund. 29 June 2021. Retrieved 2 July 2021.
  16. ^ Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, Sans C, Leighton P, Suárez P, García-Escorza H, Araos R (July 2021). "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile". New England Journal of Medicine. doi:10.1056/NEJMoa2107715. PMC 8279092. PMID 34233097. S2CID 235766915.
  17. ^ "Reporte COVID-19: Vacuna Coronavac Tiene Un 90,3% De Efectividad Para Prevenir El Ingreso a UCI" [COVID-19 report: CoronaVac vaccine is 90.3% effective in preventing admission to the ICU]. Ministerio de Salud – Gobierno de Chile (in Spanish). 17 May 2021.
  18. ^ Aditya A. "China Sinovac Shot Seen Highly Effective in Real World Study". Bloomberg. Retrieved 15 May 2021.
  19. ^ "Kajian Cepat Kemenkes : Vaksin Sinovac Efektif Cegah Kematian" [Ministry of Health Quick Study: Sinovac Vaccine Effectively Prevents Death]. Sehat Negeriku (in Indonesian). 12 May 2021. Retrieved 15 May 2021.
  20. ^ "Mass vaccination creates healthy oasis in Brazilian city". Reuters. 31 May 2021. Retrieved 2 June 2021.
  21. ^ "Sinovac vaccine restores a Brazilian city to near normal". Associated Press. 1 June 2021. Retrieved 2 June 2021.
  22. ^ González S, Olszevicki S, Salazar M, Calabria A, Regairaz L, Marín L, Campos P, Varela T, Martínez VV, Ceriani L, Garcia E (2021-10-01). "Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina". EClinicalMedicine. 40. doi:10.1016/j.eclinm.2021.101126. ISSN 2589-5370. PMC 8435263.
  23. ^ a b c "Chile realiza primer estudio a nivel mundial sobre uso de dosis de refuerzo en vacunas inactivadas: Aumenta efectividad en prevención y hospitalización por COVID-19" [Chile conducts the first study worldwide on inactivated vaccine boosters: increased effectiveness against disease and hospitalization due to COVID-19] (Press release) (in Spanish). Ministry of Health of Chile. 7 October 2021. Retrieved 11 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Template:COVID-19_vaccine_effectiveness&oldid=1205017406"